Loading...
•
Jun 30, 2020
Protalix Q2 2020 Earnings Report
Reported second quarter financial results and provided business update.
Key Takeaways
Protalix BioTherapeutics reported revenues from selling goods of $3.6 million and revenues from license and R&D services of $7.3 million for the second quarter ended June 30, 2020. The company also announced positive topline results in its BRIDGE phase III clinical trial of PRX-102 for the treatment of Fabry disease and subsequent BLA submission to the U.S. Food and Drug Administration (FDA).
Announced positive top-line data in its Phase III BRIDGE study of PRX-102 for the Treatment of Fabry disease.
Submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for PRX-102 for the treatment of Fabry disease.
Revenues from selling goods increased by 6% compared to the same period of 2019.
Cash and cash equivalents at June 30, 2020 was $4.8 million, with $35.2 million in bank deposits.
Revenue by Segment
Forward Guidance
Protalix is continuing to build for the long term and look forward to continuing to execute as they move towards the anticipated commercial launch of PRX-102 for the treatment of Fabry disease.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...